Agoracom Blog Home

Archive for the ‘Featured’ Category

INTERVIEW: Patriot 1 Technologies Discusses Superior Weapon detection Technology $PAT.ca

Posted by AGORACOM-JC at 5:49 PM on Thursday, May 25th, 2017

INTERVIEW: HPQ Discusses New Scaling Up Milestones; 62% Increase in Impurity Removal Using Low Purity Feedstock; 531% Conversion Yield Increase $HPQ.ca

Posted by AGORACOM-JC at 9:53 AM on Wednesday, May 24th, 2017

Tetra Bio-Pharma Signs Definitive Agreement for Two Products with Panag Pharma $TBP.ca

Posted by AGORACOM-JC at 4:31 PM on Tuesday, May 23rd, 2017

Tbp large

  • Signed definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation
  • Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion

OTTAWA, ONTARIO–(May 23, 2017) - Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion. The recent press release on May 17th for the filing of a patent in ocular disease combined with the patents from Panag in the ocular space make this agreement very lucrative.

Per the definitive agreement, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra will have a right of first negotiation for future cannabinoid-based products.

Tetra will work in close collaboration with Panag’s team of experts to ensure a rapid and successful development leading to marketing authorization. Panag will continue work in the development of novel products for unmet medical need and Tetra will take the lead in commercializing these novel drug products.

“We are very pleased to announce this partnership with Panag as we work towards building an innovative product pipeline focused on cannabis,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Tetra is committed to generating revenues in 2017 by launching several products in the retail market through its partnership with Panag.”

Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The total ocular anti-inflammatory market was estimated at over $3 billion in the USA in 2014 and includes conditions such as post-op inflammation, allergic conjunctivitis and inflammatory dry eye. Panag also developed a cannabinoid topical drug product for the local treatment of pain and inflammation. In 2014, the over the counter sales of topical analgesics were estimated at over $2.5 billion according to IMS.

“We will prioritize the development of the ocular therapy as this is a promising innovative product with high medical need and a significant potential financial reward,” said Guy Chamberland, Chief Scientific Officer of Tetra Bio-Pharma. Tetra has positioned itself to become a leader in topical pain relief.

Corporate Update:

Tetra changed today at the opening of the U.S. markets its OTCQB stock symbol to TBPMF.

The Company issued 501,800 new shares as part as of a service agreement as previously announced in a news release on June 20, 2016.

The Company issued an additional 250,000 new shares as part of a service agreement with MAPH Enterprises, LLC, effective May 8, 2017 to broaden U.S. investor awareness.

About Panag Pharma:

Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safenon-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in the area of pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.

About Tetra Bio-Pharma:

Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Source: Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
www.tetrabiopharma.com

Marijuana Company of America Announces the Filing of Form 10 Reg Statement with SEC + Apply for QB upgrade $MCOA.us

Posted by AGORACOM-JC at 11:16 AM on Tuesday, May 23rd, 2017

15233 mcoa

  • Filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission
  • Important step in helping the Company to raise the necessary capital to fund its projects and expand its operations, as well as provide more transparent and reliable information to investors
  • Company will apply to upgrade its trading tier with OTC Markets to the OTCQB

BONSALL, CA–(May 23, 2017) – MARIJUANA COMPANY OF AMERICA, INC (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis and hemp company, is pleased to announce that it has filed a Form 10 Registration Statement with the U.S. Securities and Exchange Commission (SEC). This is an important step in helping the Company to raise the necessary capital to fund its projects and expand its operations, as well as provide more transparent and reliable information to investors.

Once the registration statement becomes effective, the Company will apply to upgrade its trading tier with OTC Markets to the OTCQB. Upgrading to the OTCQB is an efficient way to raise the Company’s profile among the investor and broker dealer communities, access greater liquidity, and trade on an SEC-recognized market, removing many of the trading restrictions placed on Pink market securities. The Form 10 filing provides investors detailed and audited information about MCOA‘s operations, including an overview of the business strategies, risk factors and financial statements. This additional and reliable information will help our investors make a more educated investment decisions about the Company.

“Taking steps to become a fully reporting company is yet another way that we are distinguishing ourselves from most of the marijuana public companies that report under the Alternative Reporting Standards on the OTC Pink market,” said Donald Steinberg, CEO of MCOA. “MCOA experienced substantial growth in 2016 and we hope to continue this momentum throughout 2017 as well. Our Form 10 filing and ongoing SEC reporting disclosures through audited annual financial statements, auditor reviewed quarterly financial statements and all material events will provide additional transparency to our shareholders and the investment community on our performance as we grow.”

MCOA‘s Form 10 Registration Statement includes audited financial statements of the business, an overview of the markets and industries in which the Company will operate, details regarding the Company’s management, and competitive strengths, strategies and risk factors. A copy of the Form 10 is available at www.sec.gov under the name of Marijuana Company of America, Inc. Additionally, the Form 10 can be found on the Investors Relations portion of the Company’s website at www.marijuanacompanyofamerica.com

SAFE HARBOR STATEMENT
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
IR@mcoa.club

VGambling Changes Name to Esports Entertainment Group in Anticipation of Platform and Operations Launch $GMBL.us

Posted by AGORACOM-JC at 12:35 PM on Thursday, May 18th, 2017

Vgabmlinglarge copy

  • Announced its recent name change to Esports Entertainment Group, Inc.
  • Anticipation of imminent launch of eSports online wagering platform in June
  • Online wagering platform will trigger the start of our corporate and business development programs, including eSports industry and trade conferences around the world

ST. MARY’S, ANTIGUA–(May 18, 2017) – VGambling Inc. (OTCQB: GMBL) (or the “Company”), a licensed online gambling company with a specific focus on eSports wagering, is pleased to announce its recent name change to Esports Entertainment Group, Inc.

The Company elected to change its name for several reasons, first and foremost is the imminent launch of our eSports online wagering platform in June, which will be supported by both investor relations and media relations campaigns focused on the eSports industry. Our new company name will provide us far better name recognition amongst investors and within the industry, as well as, far greater search engine relevancy on both traditional and social media search engines.

Secondly, the imminent launch of our online wagering platform will also trigger the start of our corporate and business development programs, including eSports industry and trade conferences around the world, as well as, investor conferences in North America and Europe. Our new company name will provide us with greater brand recognition.

Finally, though the main focus of the Company will be its eSports online wagering platform, we intend to expand our scope of operations within the eSports entertainment and gaming industry over the next 12 months and beyond.

Grant Johnson, CEO of Esports Entertainment Group, stated, “We are pleased to announce our corporate name change because it sends a signal to the world that we are preparing to imminently launch both our eSports wagering platform and corporate development programs. This is an incredibly exciting time for our shareholders, pre-registered customers, partners and the entire eSports industry.”

NEW WEBSITE, TWITTER ACCOUNT & ONLINE INVESTOR RELATIONS

Our new corporate website, set for imminent launch, can be found at www.esportsentertainmentgroup.com

Our new Twitter account is @eSportsEntGroup and can be found at https://twitter.com/eSportsEntGroup

Our new Online Investor Relations Community on AGORACOM can be found at https://agoracom.com/ir/EsportsEntertainmentGroup

About Esports Entertainment Group

Esports Entertainment Group Inc. is a licensed online gambling company specifically focused on eSports wagering. Esports Entertainment intends to offer wagering on eSports events in a fully licensed, regulated and secured platform to the global eSports audience, excluding the United States. In addition, Esports Entertainment intends to offer users from around the world the ability to participate in multi-player video games tournaments online for cash prizes. Esports Entertainment is led by a team of industry and technical experts from the online gambling and video game industries, eSports, marketing, legal and financial professionals. The Company maintains offices in St. Mary’s, Antigua and Barbuda. Esports Entertainment common stock is listed on the OTCQB under the symbol GMBL. For more information please visit www.esportsentertainmentgroup.com.

Our Online Investor Relations Community at http://agoracom.com/ir/eSportsEntertainmentGroupprovides shareholders with the ability to post IR questions, receive answers and collaborate with fellow shareholders in a fully moderated environment.

FORWARD-LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

CONTACT INFORMATION

Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease $TBP.ca

Posted by AGORACOM-JC at 4:17 PM on Wednesday, May 17th, 2017

Tbp large

  • Submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease
  • Global market for cancer drugs has hit US$100 billion in annual sales
  • Could reach US$147 billion by 2018, according to a new report by IMS Institute for Healthcare Informatics

OTTAWA, ONTARIO–(May 17, 2017) - Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:GRPOF), today announced that Tetra has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.

The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics. According to Transparency Market Research, the global ophthalmic drug market is expected to reach US$21.6 billion by 2018 due to high incidence of eye-related disorders amongst geriatrics. The provisional patent aims to protect new pharmaceutical combinations of cannabinoids and terpenoids to inhibit a specific signaling pathway, known as Hedgehog (Hh), and their use to combat human diseases.

“Filing of this provisional patent marks the launch of an innovative and exciting project that could not only impact patients suffering from a variety of human diseases, but also further Tetra’s interests in developing and commercializing novel cannabinoid-based pharmaceutical drugs,” said Dr. Guy Chamberland, Chief Scientific Officer of Tetra. “The rationale forming the basis for this project is well founded and our research team has extensive scientific experience in the Hh field. We look forward to quickly advancing the project through key academic collaborations, with the ultimate goal of developing multiple pharmaceutical treatments.”

Background Information:

Hh signaling is a critical developmental molecular signaling pathway and inappropriate over activation of Hh is causal in several types of human tumors, including medulloblastoma, basal cell carcinoma, rhabdomyosarcoma, and multiple forms of leukemia, as well as liver, stomach, small cell lung, prostate, and breast cancers. Hh signaling also regulates the formation and remodeling of blood vessels, and aberrant blood vessel growth is implicated in several human diseases. The eye is particularly vulnerable to dysfunctional angiogenesis and neovascularization, such as in the case of diabetic retinopathy, age-related macular degeneration, neovascular glaucoma, retinal vein occlusion and retinopathy of prematurity, where inappropriate ocular blood vessel growth often leads to irreversible blindness if left untreated.

Currently, there are few clinically approved treatments for Hh-pathway-dependent cancers and drug resistance remains a major hurdle. As well, current treatment approaches to neovascular and angiogenic ocular disease are insufficiently effective and have significant adverse effects. Thus, there is a large need to develop novel therapies to treat human cancers and ocular disease related to blood vessel growth. Recently, cannabinoids have emerged as novel and potent inhibitors of the Hh signaling pathway and terpenoids have been shown to modulate the effects of cannabinoids through an undefined mechanism. Tetra looks to capitalize on these recent findings by filing a provisional patent for the use of cannabinoids in combination with terpenoids to treat Hh related cancer growth and aberrant blood vessel growth in the eye. Securing a provisional patent and achieving the freedom to operate is an important first step in the realization of this project.

About Tetra-Bio Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com

PyroGenesis Provides 2nd Progress Report to HPQ Silicon Resources; 62% Increase in Impurity Removal; 531% Yield Increase $PYR.ca

Posted by AGORACOM-JC at 8:48 AM on Tuesday, May 16th, 2017

Pyr header 1

  • Submitted  “Update on the PUREVAP™ progress report to HPQ Silicon Resources Inc.
  • 62% Increase in Impurity Removal
  • 531% Yield Increase

MONTREAL, QUEBEC–(May 16, 2017) - PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX VENTURE:PYR)(OTCQB:PYRNF), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma waste-to-energy systems and plasma torch products, is pleased to announce today that, further to its press release dated January 26, 2017, it has submitted a progress report to HPQ Silicon Resources Inc. (“HPQ”) entitled “Update on the PUREVAP™ Process Characterization Testing #2“, which covers the period since the last technical report. The salient points of the report are significant in that they validate the systematic and methodical approach to the lab scale test purification work, and the scaling up of the process to convert quartz into high purity silicon metal.

The report confirms that recent, and ongoing, modifications to the PUREVAP™ process have resulted in: (i) a 62% improvement in the impurity removal capacity of the system using low purity quartz as feedstock and (ii) a 531% increase in yield of the silicon (Si) produced.

“We are pleased with the progress to date,” said Pierre Carabin, Chief Technology Officer of PyroGenesis. “We have now reached a stage where we can start testing using high purity feedstock which will allow us to validate the impurity removal capacity of the lab scale reactor and ultimately, to further improve the product purity.”

Having successfully secured access to high purity quartz (99.5% SiO2), the next phase will apply high efficiency impurity removal techniques to this higher purity feedstock. The objective of using a higher purity feedstock is to test the ability to reach the 5N (99.999%) benchmark at lab scale, and furthermore, to provide additional data which will help PyroGenesis with the final design of the pilot plant reactor. These tests will commence as soon as the latest process improvements are completed.

“These results demonstrate that the PUREVAP™ QRR quartz purification process can continue to be successfully improved while using low purity feedstock at the bench scale. This represents yet more important technical milestones being reached in our path toward production of Solar Grade Silicon Metal. At this stage of our development, we continue to pass critical milestones consistently and must continue our ‘iterative’ approach of incrementally increasing size, and purity step by step”, said Bernard Tourillon, Chairman and CEO of HPQ. “Building on our scaling up success to date, the coming months should allow us to continue to make improvements to our scaling up program, while simultaneously testing for the best and greenest pathway to produce 5N (99.999% Si) Solar Grade Silicon Metal at lab scale, prior to start-up of the Pilot plant scheduled for 2018.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. PyroGenesis provides engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Its core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Its operations are ISO 9001:2008 certified, and have been ISO certified since 1997. PyroGenesis is a publicly-traded Canadian company on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace (Ticker Symbol: PYRNF). For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTC Markets Group Inc. accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

PyroGenesis Canada Inc.
Rodayna Kafal
VP, Investor Relations and Communications
(514) 937-0002
ir@pyrogenesis.com
rkafal@pyrogenesis.com

New Scaling Up Milestones; 62% Increase in Impurity Removal Using Low Purity Feedstock; 531% Conversion Yield Increase $HPQ.ca

Posted by AGORACOM-JC at 8:07 AM on Tuesday, May 16th, 2017

Hpq large

  • New Scaling Up Milestones
  • 62% Increase in Impurity Removal Using Low Purity Feedstock
  • 531% Conversion Yield Increase

HPQ Silicon Resources Inc (“HPQ”) (TSX VENTURE:HPQ)(FRANKFURT:UGE)(OTC PINK:URAGF) is pleased to inform its shareholders that PyroGenesis Canada Inc (“PyroGenesis”) has submitted a new stage report entitled “Update on The PUREVAPtm Process Characterization Testing #2” pertaining to tests completed since our last technical PR (26/01/17). The objectives of test #37 to #74 was increasing Si yield at lab scale by continuously improving process parameter and implementing alternative purification routes while still using low purity feed stock. The salient points of the report are significant in that they validate our systematic and methodical approach to our bench scale test purification work and scaling up our process of converting quartz into high purity silicon metal.

PROCESS IMPROVEMENT SHOWING SIGNIFICANT POTENTIAL TOWARD REACHING HIGHER PURITY

The report confirms that ongoing modifications to the PUREVAP™ QRR process have resulted in a 62% improvement in the impurity removal capacity of the system. This outcome is based on third party laboratory results1, comparing the total average impurities count of 856.6 ppm (99.91%) for the Si produced by test #24 completed prior the modification with the total impurity count result of 328.98 ppm (99.97%) for the Si produced by test #51 completed after, using the same low purity quartz feedstock with total impurity count of 18,900 ppm (98.14 SiO2).

Bernard Tourillon, Chairman and CEO of HPQ-Silicon stated, “These results demonstrate that the PUREVAPtm QRR quartz purification process can continue to be successfully improved while using low purity feedstock at the bench scale. This represents yet more important technical milestones being reached in our path toward production of Solar Grade Silicon Metal. At this stage of our development, we continue to pass critical milestones consistently and must continue our ‘iterative’ approach of incrementally increasing size, and purity step by step”.

Table 1: Removal efficiency of main impurities from Si Sample

Removal efficiency
Element Test#24 Test#51
Al 72.0% 93.9%
Ca 95.5% 98.8%
Fe 98.1% 99.3%
Mg 97.0% 99.9%
Mn 98.5% 99.5%
Na 99.6% 100.0%
K 96.4% 100.0%
Ti -15.0% 79.8%
P 44.7% 53.1%
S 99.9% 100.0%
W 55.6% 100.0%
B 34.0% 44.3%
Average 73.0% 89.1%
1 Analyses completed by Evans Analytical Group, (“EAG” of Liverpool, NY, USA) – using Glow Discharge Mass Spectrometry (“GDMS”)

Results for key impurities from test 51 indicate that the process modification implement are now allowing removal efficiencies of 100% for Na, K, S and W, > 99% for Fe, Mg and Mn, 98.8% for Ca, 93.9% for Al, 79.8 % for Ti (one of the most difficult impurity to remove), 53.1% for P and 44.3% for B.

Final results regarding process improvement using lower quality feedstock in test #54 to #74 will be reported once analysed by third party laboratory. PyroGenesis will submit a technical proposal to HPQ shortly, highlighting the best way to proceed with the final batch, based upon process and test results to date.

TESTING USING FEEDSTOCK WITH 99.5% SiO(500 PPM OF IMPURITIES) BECOMES KEY FOCUS

Once the results from samples #54 to #74 are completed, the effort will focus on applying purification techniques to higher purity quartz feedstock. Presently the industry produces standard grade Si (MG-Si 98-99% Si) using as feedstock a quartz with no more then 500 ppm of impurities (99.5% SiO2) and a maximum iron oxide (Fe) content of 0.1-0.15 wt%.

With the exception of the proof of concept phase, all of the tests to date that produced 99.9+% Si were completed using quartz feed stock with a total impurity count of 18,900 ppm (98.14 SiO2) and iron oxide (Fe) content of 0.9 wt%, or 9 times greater than the industry standard for Fe.

Having successfully secured access to high purity Quartz (99.5% SiO2) from both HPQ – owned quartz deposits and from outside suppliers, the next phase will apply the high efficiency impurities removal techniques to the higher purity feedstock. The objective of using the higher purity feedstock is to test the ability to reach the 5N threshold at the bench scale, and provide more data necessary for the final design of the pilot plant. These tests will commence as soon as the latest process improvements announced in our May 4, 2017 PR, are completed on the lab scale PUREVAP™ QRR.

“We are pleased with the progress to date,” said Pierre Carabin, Chief Technology Officer of PyroGenesis. “We have now reached a stage where we can start testing using high purity feedstock which will allow us to validate the impurity removal capacity of the lab scale reactor and ultimately, to further improve the product purity.”

TESTING CONTINUES TO CONFIRMS BENCH TEST SCALABILITY OF PUREVAP™ QRR PROCESS

The report confirms that process modifications done to the PUREVAP™ QRR are responsible for a 531% increase in yield of the Si produced. This is based on the fact that the process modifications has made it possible to produce the same quantity of material as produced by test #32 (PR January 26, 2017) using smaller batch size (55 wt% less) without sacrificing the purity of the final product.

Bernard J. Tourillon, Chairman and CEO of HPQ Silicon stated, “Building on our scaling up success to date, the coming months should allow us to continue to make improvements to our scaling up program, while simultaneously testing for the best and greenest pathway to produce 5N (99.999% Si) Solar Grade Silicon Metal at lab scale, prior to start-up of the Pilot plant scheduled for 2018.”

Pierre Carabin, Eng., M. Eng., has reviewed and approved the technical content of this press release.

About HPQ Silicon

HPQ Silicon Resources Inc is a TSX-V listed junior exploration company planning to become a vertically integrated and diversified High Value Silicon Metal (99.9+% Si), and Solar Grade Silicon Metal (99.999+% Si) producer.

Our business model is focused on developing a disruptive High Purity and Solar Grade Silicon Metal manufacturing process (patent pending) and becoming a vertically – integrated High Value Silicon Metal and Solar Grade Silicon producer that can generate high yield returns and significant free cash flow within a relatively short time line.

Disclaimers:

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the image accompanying this press release, please visit the following link: http://www.marketwire.com/library/20170515-test32and51_800.jpg

To view the results from Test # 24, please visit this link: http://media3.marketwire.com/docs/Test_24.pdf

To view the results from Test # 51, please visit this link: http://media3.marketwire.com/docs/Test_51.pdf

Shares outstanding: 168,987,616

Bernard J. Tourillon
Chairman and CEO
(514) 907-1011

Patrick Levasseur
President and COO
(514) 262-9239
www.HPQSilicon.com

FEATURE: Monarques Gold (TSX-V: MQR) Flagship Croinor Gold Mine Has Great Potential To Become A Producer MQR.ca

Posted by AGORACOM-JC at 11:47 AM on Wednesday, May 10th, 2017

Monarquesgold hub large

Why Monarques Gold?

  • Flagship Croinor Gold Mine Has Great Potential To Become A Producer
  • Company Is Well Financed, Including $9 Million In Credits From Quebec Government
  • Recently acquired 750 ton-per-day Beacon mill
  • Major Shareholders include: Rob McEwen and Nemaska Lithium

Croinor Gold Property

Flagship project at the prefeasibility stage

  • 100% interest in the Croinor Gold property, a gold mine project that is currently at the prefeasibility stage
  • Property consists of one mining lease and two non-contiguous blocks of claims for a total of 335 claims over a 151 km² area. A 1.5% NSR is applicable on the mining lease and only 44 claims.
  • Drilling program will test a diorite-hosted gold-bearing zone that returned grades of up to 38.7 g/t Au over 3.8 metres in historical drilling (see release)

WATCH OUR CORPORATE VIDEO

Check Out Croinor Gold
Prefeasability Study

Simkar Gold Property

NI 43-101 Gold Resource 20 km from Val-d’Or

  • 100% interest in the Simkar Gold property
  • located 20 kilometres east of Val-d’Or, in the heart of the Abitibi Greenstone Belt.
  • Comprised of two mining concessions and 15 claims covering an area of 5 km², and is subject to a 1.5% NSR.
  • NI 43-101 (click here)

The Simkar Gold property is the result of a merger of the Simkar and Texsol properties. The transaction was announced by way of press release on June 26, 2014.

Regcourt Gold Property – Val d’Or

  • 100% interest in the Regcourt Gold property
  • Property is located at the eastern end of the Val-d’Or gold mining camp, some 30 km east of Val-d’Or, and is easily accessible via Route 117.
  • Consists of 94 claims covering an area of 38 km2 near the centre of the western border of Vauquelin Township
  • Property is subject to a 1.5% and 2.5 % NSR.

 

12 Month Stock Chart

NAM Commences 2017 Exploration Program At The River Valley Pgm Project $NAM.ca

Posted by AGORACOM-JC at 9:30 AM on Wednesday, May 10th, 2017

New age large

  • Closed $2,614,762 Private Placement, April 27, 2017
  • Signed contract with Abitibi Geophysics to commence surface geophysical program
  • Projects cover 16 km long River Valley PGM deposit
  • River Valley is the Largest Undeveloped Primary PGM resource in Canada, with 2.5 Moz PGM, in Measured Plus Indicated mineral resources and near-surface covering over 16kms of strike
  • New discovery in 2015: 3.91 g/t Pd+Pt/9m from 145m in drill hole 2015-DN002
  • Discovery confirmed in 2016: 4.07 g/t Pd+Pt/9m from 202m in drill hole DN-T2-06
  • Upon completion of the geophysical program, drilling slated for summer 2017.

MAY 10, 2017 Vancouver, Canada – New Age Metals Inc. (“NAM” and the “Company”) (TSX.V: NAM; OTCQB: PAWEF) is pleased to announce that the Company plans to commence its 2017 Exploration Program this spring with a surface geophysical program at the Pine Zone of the River Valley platinum group metal (PGM) deposit near Sudbury, Ontario (Figure 1). The Pine Zone is one of many PGM zones within the district-scale River Valley PGM Project and was most recently drilled in the fall of 2016 (see to press release dated December 13, 2016). The 2016 drill program confirmed the higher-grade, near-surface PGM discovery made previously in the 2015 drill program (see press release dated March 11, 2015) and highlighted the continuity of the mineralization for 200 metres along strike and 100-200 metres depth. The Pine Zone remains open along strike and at depth. The surface geophysical survey will be performed to test the potential for eastwards and southwards extension of the Pine Zone and aid generation of new targets for drill testing later in 2017.

The 2017 Exploration Program will begin in May-June with cutting of a line grid for the surface geophysical induced polarization (IP) survey. The IP survey itself will consist in part of a detailed orientation survey to record geophysical responses over known geologic features and higher-grade PGM mineralization located in the Pine Zone and the adjacent Dana North Zone (Figure 2). The orientation survey will produce a geophysical fingerprint, which can be used to target favorable geologic features and potentially identify additional blind, structurally controlled PGM mineralization to the east, down-dip and up-dip of the Pine Zone, and elsewhere at River Valley for drill testing. Approximately 2 km of untested potential for discovery of additional mineralization presently exists along strike between the current drilled extent of the Pine Zone and the under explored Pardo Zone to the northwest (Figure 2).

The geophysical survey will be a high-resolution OreVision(R) IP survey performed by Abitibi Geophysics (Thunder Bay, Ontario). OreVision IP can reveal targets at four times the depth of conventional IP without compromising near-surface resolution. The survey size will be 20 line-km over an area measuring 1.1 sq km (Figure 3). The survey will be performed along NW-SE trending, 50m to 100m spaced cut-lines across the apparent strike direction of the geological features controlling the Pine Zone. The depth of investigation is planned to be 440m, which is 40m below the maximum predicted depth of the Pine Zone in this area. In addition to the OreVision(R) IP survey, Abitibi Geophysics will also survey two open drill holes through the host geology and PGM mineralization for physical property measurements. The physical property data will benefit 3D inversion and modelling of the OreVision(R) survey dataset, thereby aiding generation of high priority targets for drill testing. Target generation will be followed by a ~5000 metre drill program in the summer or fall of 2017.


Click Image To View Full Size

Figure 1. Location of NAM’s 100% owned River Valley PGM Project.


Click Image To View Full Size

Figure 2. Property scale geological map showing the location of the Pine Zone discovery relative to the Dana North Zone immediately to the west and the Pardo Zone 2 km to the northeast. Note the apparent dextral sense of offset of the River Valley PGM deposit (red) across the Grenville Front Tectonic Zone.


Click Image To View Full Size

Figure 3. Design map grid for the OreVision(R) IP surface survey in the Pine Zone-Dana North Zone (DNZ) area of the River Valley PGM Project. WBSZ = West Boundary Shear Zone. Solid black circles = diamond drill hole collar locations.

ABOUT NAM’S PGM DIVISION

NAM’s flagship project is its 100% owned River Valley PGM Project (NAM Website – River Valley Project) in the Sudbury Mining District of NW Ontario (100 km east of Sudbury, Ontario). Presently, the River Valley Project has Measured + Indicated resources of 91 million tonnes @ 0.58 g/t* Palladium, 0.22 g/t Platinum, 0.04 g/t Gold, at a cut-off grade of 0.8 g/t for a PdEq of 2,463,000 ounces PGM plus Gold. The River Valley PGM-Copper-Nickel Sulphide mineralized zones remain open to expansion and are undergoing continued exploration.

In 2016, the company acquired the River Valley extension property which added approximately 4kms to the project mineralized strike length.

ABOUT NAM’S LITHIUM DIVISION

The Company has several Hard Rock Lithium Projects in Canada:

To date the Company has acquired 5 hard rock (Pegmatite) Lithium Projects, in the Winnipeg River Pegmatite Field, in SE Manitoba. This Pegmatite Field hosts the giant Tanco Pegmatite that has been mined for Tantalum, Cesium and Spodumene (one of the primary Lithium ore minerals) in varying capacities, since 1969. Today, the Tanco Mine is focused on the mining of Pollucite (primary Cesium ore) and the production of Cesium Formate, a completion drilling fluid for the petroleum industry. NAM’s Lithium Projects are strategically situated in this prolific Pegmatite Field. Presently, NAM is the largest mineral claim holder in the Winnipeg River Pegmatite Field and is seeking JV partners to further develop the company’s Li division.

The Company also announces that it has issued an aggregate of 287,954 common shares to Agora Internet Relations Corp. (“AGORACOM”). The securities issued represent the payment for services under the terms of an existing agreement and are subject to a four month plus one day hold period expiring September 3, 2017.

QUALIFIED PERSON

The contents contained herein that relate to Exploration Results or Mineral Resources is based on information compiled, reviewed or prepared by Dr. Bill Stone, Principal Consulting Geoscientist for Pacific Northwest Capital. Dr. Stone is the Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the technical content of this news release.

On behalf of the Board of Directors

“Harry Barr”

Harry G. Barr

Chairman and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.